Literature DB >> 29930712

Role of interleukin-32 in cancer biology.

Haimeng Yan1, Donghua He1, Xi Huang1, Enfan Zhang1, Qingxiao Chen1, Ruyi Xu1, Xinling Liu1, Fuming Zi2, Zhen Cai1.   

Abstract

Interleukin-32 (IL-32), a novel proinflammatory cytokine, is highly expressed in various cancer tissues and in established cancer cell lines. IL-32 has been revealed to serve a crucial role in human cancer development, including tumour initiation, proliferation and maintenance. The expression of IL-32 is regulated by numerous factors, including genetic variations, hypoxia and acidosis in the tumour microenvironment. Understanding the underlying mechanisms of IL-32 expression and its function are critical for the discovery of novel therapeutic strategies that target IL-32. This is a review of the current literature on the regulation and function of IL-32 in cancer progression, focusing on the molecular pathways linking IL-32 and tumour development.

Entities:  

Keywords:  cancer; interleukin-32; mechanisms; regulation

Year:  2018        PMID: 29930712      PMCID: PMC6006503          DOI: 10.3892/ol.2018.8649

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  66 in total

1.  Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane-associated protein.

Authors:  Haruki Hasegawa; Heather J Thomas; Ken Schooley; Teresa L Born
Journal:  Cytokine       Date:  2011-01       Impact factor: 3.861

2.  IL-32 promotes angiogenesis.

Authors:  Claudia A Nold-Petry; Ina Rudloff; Yvonne Baumer; Menotti Ruvo; Daniela Marasco; Paolo Botti; Laszlo Farkas; Steven X Cho; Jarod A Zepp; Tania Azam; Hannah Dinkel; Brent E Palmer; William A Boisvert; Carlyne D Cool; Laima Taraseviciene-Stewart; Bas Heinhuis; Leo A B Joosten; Charles A Dinarello; Norbert F Voelkel; Marcel F Nold
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

3.  Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells.

Authors:  Charn-Jung Chang; Yueh Chien; Kai-Hsi Lu; Shih-Ching Chang; Yueh-Ching Chou; Chi-Shuan Huang; Chin-Hong Chang; Kuan-Hsuan Chen; Yuh-Lih Chang; Ling-Ming Tseng; Wen-Shin Song; Jhi-Joung Wang; Jen-Kou Lin; Pin-I Huang; Yuan-Tzu Lan
Journal:  Biochem Biophys Res Commun       Date:  2011-10-19       Impact factor: 3.575

4.  Interleukin-32: a cytokine and inducer of TNFalpha.

Authors:  Soo-Hyun Kim; Sun-Young Han; Tania Azam; Do-Young Yoon; Charles A Dinarello
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

5.  Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10.

Authors:  Huimin Tao; Lin Lu; Yang Xia; Fu Dai; Yi Wang; Yangyi Bao; Steven K Lundy; Fumito Ito; Qin Pan; Xiaolian Zhang; Fang Zheng; Guoshun Shu; Bingmu Fang; Jinhong Jiang; Jianchuang Xia; Shiang Huang; Qiao Li; Alfred E Chang
Journal:  Eur J Immunol       Date:  2015-01-21       Impact factor: 5.532

6.  A promoter polymorphism in human interleukin-32 modulates its expression and influences the risk and the outcome of epithelial cell-derived thyroid carcinoma.

Authors:  Theo S Plantinga; Irene Costantini; Bas Heinhuis; Angelique Huijbers; George Semango; Benno Kusters; Mihai G Netea; Ad R M M Hermus; Jan W A Smit; Charles A Dinarello; Leo A B Joosten; Romana T Netea-Maier
Journal:  Carcinogenesis       Date:  2013-03-13       Impact factor: 4.944

7.  Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer.

Authors:  Nasser Ghaly Yousif; Fadhil G Al-Amran; Najah Hadi; Jillen Lee; Jonthan Adrienne
Journal:  Cytokine       Date:  2012-10-26       Impact factor: 3.861

8.  Interaction network mapping among IL-32 isoforms.

Authors:  Jeong-Woo Kang; Yun Sun Park; Dong Hun Lee; Man Sub Kim; Yesol Bak; Sun Young Ham; Su Ho Park; Heejong Kim; Joong Hoon Ahn; Jin Tae Hong; Do-Young Yoon
Journal:  Biochimie       Date:  2014-01-25       Impact factor: 4.079

Review 9.  Novel insights into the biology of interleukin-32.

Authors:  Leo A B Joosten; Bas Heinhuis; Mihai G Netea; Charles A Dinarello
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

10.  Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer.

Authors:  Mohd Saif Zaman; Sobha Thamminana; Varahram Shahryari; Takeshi Chiyomaru; Guoren Deng; Sharanjot Saini; Shahana Majid; Shinichiro Fukuhara; Inik Chang; Sumit Arora; Hiroshi Hirata; Koji Ueno; Kamaldeep Singh; Yuichiro Tanaka; Rajvir Dahiya
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

View more
  7 in total

1.  Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma.

Authors:  Haimeng Yan; Donghua He; Jianwei Qu; Yang Liu; Ruyi Xu; Huiyao Gu; Jing Chen; Yi Li; Enfan Zhang; Yi Zhao; Jingsong He; Zhen Cai
Journal:  Cancer Immunol Immunother       Date:  2022-07-26       Impact factor: 6.630

2.  Inhibition of IL-32 Expression Ameliorates Cerebral Ischemia-Reperfusion Injury via the NOD/MAPK/NF-κB Signaling Pathway.

Authors:  Chao Liu; Xiaohui Xu; Chao Huang; Dandan Shang; Li Zhang; Yupeng Wang
Journal:  J Mol Neurosci       Date:  2020-05-30       Impact factor: 3.444

3.  Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells.

Authors:  Christophe Deben; Laurie Freire Boullosa; Andreas Domen; An Wouters; Bart Cuypers; Kris Laukens; Filip Lardon; Patrick Pauwels
Journal:  Cancer Drug Resist       Date:  2021-03-19

4.  Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators.

Authors:  Ahmad Faisal Karim; Anthony R Soltis; Gauthaman Sukumar; Christoph Königs; Nadia P Ewing; Clifton L Dalgard; Matthew D Wilkerson; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

Review 5.  The New Old CD8+ T Cells in the Immune Paradox of Pregnancy.

Authors:  Lilja Hardardottir; Maria Victoria Bazzano; Laura Glau; Luca Gattinoni; Angela Köninger; Eva Tolosa; Maria Emilia Solano
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

6.  Comparison of the Seven Interleukin-32 Isoforms' Biological Activities: IL-32θ Possesses the Most Dominant Biological Activity.

Authors:  Saerok Shim; Siyoung Lee; Yasmin Hisham; Sinae Kim; Tam T Nguyen; Afeisha S Taitt; Jihyeong Hwang; Hyunjhung Jhun; Ho-Young Park; Youngmin Lee; Su Cheong Yeom; Sang-Yeob Kim; Yong-Gil Kim; Soohyun Kim
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 7.561

Review 7.  Biological Role, Mechanism of Action and the Importance of Interleukins in Kidney Diseases.

Authors:  Paulina Mertowska; Sebastian Mertowski; Iwona Smarz-Widelska; Ewelina Grywalska
Journal:  Int J Mol Sci       Date:  2022-01-07       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.